Mirum’s Long-Term Alagille Data Support Case For Early Filing

Newly public Mirum hopes to file maralixibat for US approval in pruritus due to Alagille syndrome based on Phase IIb data, including long-term extension data reported at AASLD.

Liver Meeting Update, Boston 2019
Mirum is advancing former Shire compounds in cholestatic liver disease

Since acquiring a pair of mid-stage apical sodium-dependent bile acid transporter (ASBT) inhibitors from Shire PLC in 2018, Mirum Pharmaceuticals has been working to build a case for both in pediatric cholestatic liver disease. Now, with long-term extension data, the company hopes to convince the US Food and Drug Administration on filing maralixibat for pruritus related to Alagille syndrome on the strength of Phase IIb data.

More from Strategy

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By 

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By 

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By 

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.

More from Business

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By 

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.

Baxdrostat, AstraZeneca’s Next Big CVRM Bet

 
• By 

The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By 

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.